June 2014, Vol 3, No 4
The Evolution of Personalized Medicine in OncologyLetter to Our Readers
To Our Reading Community,
It gives me great pleasure to present this issue of Personalized Medicine in Oncology (PMO). We constantly and thoroughly examine every aspect of our journal – appearance, readability, and, most importantly, editorial content. With input from our expert editorial board and our readership, we are always expanding and improving our content to bring you the information you need to continue growing in your knowledge of personalizing treatment for your patients.
You will see the results of our efforts in the following ways:
The Biomarker. Under the direction of our editorial board member and pathologist Dr Pranil Chandra, we introduced this department to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact of that marker.
The Last Word. Beginning in the July/August issue of PMO, we are pleased to have Dr Edward Abrahams from the Personalized Medicine Coalition author this department. In this thought-provoking column, Dr Abrahams will provide insights on the hot topics surrounding personalized medicine.
QR codes. You will begin to notice more QR codes in our pages to conveniently bring you more information related to the topics presented.
Interview With the Innovators. The world of personalized medicine is a rapidly changing and ever-evolving state involving many stakeholders on the front lines of its creation: physicians, industry, researchers, patient advocates, and payers. PMO seeks out the leaders in these sectors and brings you their game-changing strategies, missions, and impact on personalized oncology care.
We believe these features will greatly enrich your reading experience and enhance your knowledge of the world of personalized medicine. Please let us know what you think by e-mailing our editorial director at email@example.com. We look forward to and welcome your feedback.
Sanjiv S. Agarwala, MD
Coeditor in Chief
Personalized Medicine in Oncology
HER2+/HR– Breast Cancer Subtype Identified as Biomarker Signature for Neratinib Use A multitargeted kinase inhibitor met criteria for a phase 3 clinical trial in breast cancer after statistical modeling of clinical data showed a high probability of success versus standard therapy for patients with HER2-positive/hormone receptor (HR)-negative (HER2+/HR–) disease. Neoadjuvant [ Read More ]
PMO is pleased to offer the department The Biomarker to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. Do you have a unique case to share with our reading community? Please submit your biomarker-driven cases to us at [ Read More ]